PFS for each cohort and PFS stratified by PD-L1 CPS status.
toxicity, non-coronavirus disease pneumonia, carcinoid crisis 1 (0.8%)
DISEASE PROGRESSION, SECONDARY NEOPLASM
PFS for each cohort (A total of 77 (62.6%) patients died throughout the study period, due to disease progression 69 (56.1%), toxicity 3 (2.4%), clinical deterioration 1 (0.8%), carcinoid crisis 1 (0.8%), progression of secondary neoplasm 1 (0.8%), cerebrovascular incident 1 (0.8%), and non-coronavirus disease pneumonia 1 (0.8%). The median OS was not reached (range: 0.3–41.3) in lung-NETs (Cohort 1) and was 29.5 (95% CI: 19.6–39.4), 23.8 (95% CI: 16.4–31.2), and 5.9 (95% CI: 2–9.7) months for cohorts 2 to 4, respectively (Fig. 